In the case of Mylan NV (NASD: MYL), the market cap is now $33.25 billion ... GIS plotted in green): Below is a three month price history chart comparing the stock performance of MYL vs. GIS: Another reason market …
Forbes · 12 minutes ago
market capitalization
In-depth coverage >
Separately, analysts at BTIG Research initiated coverage on shares of Mylan in a research note on Friday, June 19th. They set a “buy” rating and a $85.00 price target on the stock. Mylan (NASDAQ:MYL) opened at …
Ticker Report · 1 day ago
MORGANTOWN — Teva Pharmaceutical Industries announced Friday morning, June 19, that it has purchased 4.61 percent of Mylan NV stock shares, which enables it to begin court proceedings before the Dutch … · 6/19/2015
More from Bing News
Mylan NV (NYSE:MYL) opened at 69.06 on Monday. Mylan NV has a 52 week low of $44.80 and a 52 week high of $76.69. The stock’s 50-day moving average is $71. and its 200-day moving average is $62.. The company has a market cap of $33.84 … · 6/29/2015
Mylan NV (NYSE:MYL) Director Melina E. Higgins sold 8,351 shares of Mylan NV stock on the open market in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $73.08, for a total value of $610,291.08. The sale …
Mideast Times · 6/18/2015
Mylan NV
Last week, CFO John Sheehan met with Perrigo shareholders in Israel to tout the benefits of a tie-up; he also promised to list Mylan on the Tel Aviv stock exchange and keep open at least one Israeli manufacturing …
FiercePharma · 1 day ago
TEL AVIV: Mylan NV chief financial officer John Sheehan will arrive in Israel on Wednesday for a meeting with the head of the Tel Aviv Stock Exchange to discuss a possible listing of its shares if it succeeds in buying …
Economic Times · 6/23/2015
Tel Aviv
Teva has so far spent $1.5 billion on purchasing Mylan stock. In a step that is apparently an attempt to allay fears of the stichting, the independent body that could exercise an option to buy new preferred shares … · 6/22/2015
Perrigo, which is opposing Mylan’s cash-and-stock bid, objected to Mylan using the figure, saying it should be treated as a forecast under Irish takeover rules. On May 27, Mylan issued a statement saying that although the $6 figure was a target ...
Pittsburgh Post-Gazette · ByLen Boselovic · 6/26/2015
Below is a chart of Mylan NV versus Devon Energy Corp. plotting their respective ... sharp minds individually came to the same bullish conclusion, and therefore the stock should do well... but it could also mean that if …
The Street · 6/26/2015


Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters …
Mylan N.V. is a global generic and specialty pharmaceuticals company registered in the Netherlands and with operational headquarters in Hatfield, Hertfordshire in the United Kingdom. In 2007, Mylan acquired a controlling interest in India-based Matrix Laboratories Limited, a top producer of active pharmaceutical ingredients for generic drugs, and the generics business of Germany-based Merck KGaA. Through these acquisitions, Mylan has grown from the third-largest generic and pharmaceuticals company in the United States to the second-largest generic and specialty pharmaceuticals company in the world. Mylan now has approximately 22,000 employees, more than 1,000 separate products, and serves customers in more than 150 countries and territories. Mylan has a global manufacturing output of more than 45 billion doses.
Data from: Wikipedia · Freebase